PHASE 3 CLINICAL TRIALS
\fˈe͡ɪz θɹˈiː klˈɪnɪkə͡l tɹˈa͡ɪə͡lz], \fˈeɪz θɹˈiː klˈɪnɪkəl tɹˈaɪəlz], \f_ˈeɪ_z θ_ɹ_ˈiː k_l_ˈɪ_n_ɪ_k_əl t_ɹ_ˈaɪ_əl_z]\
Sort: Oldest first
-
Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.